Concerns about a potentially fatal side effect have crushed plans to market modafinil as a treatment for attention deficit hyperactivity disorder (ADHD). A proposal to market it for treating ADHD hit a snag in March when a child taking part in a clinical trial developed a life-threatening skin condition (New Scientist, 1 April, p 8).
Manufacturer Cephalon of Frazer, Pennsylvania, tried to convince the Food and Drug Administration that the child's rash was not a reaction to the drug. It has now abandoned its ADHD plans after the FDA refused to approve modafinil without further extensive safety studies.
"It's really unfortunate," says James Swanson, a psychologist at the University of California, Irvine, who was involved in Cephalon's ADHD trials. He still believes modafinil is safer than other stimulants, which may cause hallucinations in a minority of children.
Documenting Psychiatrists Behaving Badly
Of all professions, psychiatrists seem to get into the most trouble. I have been collecting stories about psychiatric screwups for a while. Sadly, it has been disgustingly easy to do. We post stories with links to the original sources. We couldn't make this stuff up if we wanted to. My Name is Sickmind Fraud.
Saturday, August 19, 2006
Fatal Side Effect Stops New Psych Drug
Information From New Scientist Here is the info without the feel good marketing
No comments:
Post a Comment